ABC | Volume 110, Nº6, Junho 2018

Artigo Original Reis et al Miocardiopatia Hipertrófica Arq Bras Cardiol. 2018; 110(6):524-531 TreatmentofHypertrophicCardiomyopathy-AReportoftheAmericanCollege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J AmColl Cardiol. 2011;58(25):e212-60. 11. O’Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013 Apr;99(8):534-41. 12. Beadle R, Williams L. Device therapy in hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2010;8(12):1767-75. 13. Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten CateFJ,etal.Validatonofthe2014EuropeanSocietyofCardiologyGuidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophiccardiomyopathy.CircArrhythmElectrophysiol.2015;8(4):829-35. 14. MaronBJ,CaseySA,ChanRH,GarberichRF,RowinEJ,MaronMS.Independent assessment of the European Society of Cardiology sudden death riskmodel for hypertrophic cardiomyopathy. AmHeart J. 2015;116(5):757-64. 15. O’Mahony C, Jichi F, PavlouM, Monserrat L, Anastasakis A, Rapezzi C, et al; Hypertrophic CardiomyopathyOutcomes Investigators. A novel clinical risk predictionmodel for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010-20. 16. Kelley-Hedgepeth A, Maron MS. Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Curr Heart Fail Rep. 2009;6(3):135-41. 17. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010;121(3):445-56. 18. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342(6):365-73. 19. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta- analysis. Circ Heart Fail. 2012;5(5):552-9. 20. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527-35. 21. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J AmColl Cardiol. 2014;64(1):83- 99. Erratum in: J Am Coll Cardiol. 2014;64(11):1188. 22. Maron BJ, Rowin EJ, Casey SA, LinkMS, Lesser JR, Chan RH, et al. Hypertrophic cardiomyopathyassociatedwithlowcardiovascularmortalitywithcontemporary managementstrategies.JAmCollCardiol.2015;65(18):1915-28. 23. Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1085-92. 24. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;106(10):1481-6. 25. Elliot PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. 26. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527-35. 27. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. 28. Maron BJ, Rowin EJ, Casey AS, Haas TS, Chan RH, Udelson JE, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy over 60 years of age. Circulation. 2013;127(5):585-93. 29. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95. 30. Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. Circulation. 2015;132(4):292-8. 31. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74. 32. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of the gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-7. 33. Caetano F, Botelho A, Trigo J, Silva J, Almeida I, Venâncio M, et al. Phenotypic expression in hypertrophic cardiomyopathy and late gadoliniumenhancement on cardiacmagnetic resonance. Rev Port Cardiol. 2014;33(5):261-267. 34. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541-9. 35. Harris KM, Spirito P, MaronMS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-25. 36. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108(19):2342-8. 37. MaronMS, Olivotto I, Betocchi s, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348(4):295-303. 38. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelias ED, Charalampidis P, Savvopoulos G, et al. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(5):695-9. 39. Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, et al. Left atrialremodeling inhypertrophiccardiomyopathyandsusceptibilitymarkers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014;113(8):1394-400. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 531